Drugs / CDR132L
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07656454 | Jun → Dec 2026 expected | heart failure | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 1 | NCT04045405 | Jun 2019 → Jan 2020 | heart failure | Cardior Pharmaceuticals GmbH | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT06979375 | Jun 2025 → May 2027 expected | heart failure | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 2 | NCT06979362 | Jun 2025 → Nov 2027 expected | heart failure | Novo Nordisk A/S | Recruiting | No outcome recorded |
| Phase 2 | NCT05953831 | Apr 2024 → Sep 2025 | diastolic heart failure | Cardior Pharmaceuticals GmbH | Withdrawn | No outcome recorded |
| Phase 2 | NCT05350969 | Jul 2022 → Sep 2024 | acute myocardial infarction, left ventricular failure | Cardior Pharmaceuticals GmbH | Completed | Missed primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDR132L | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06979375 ↗ |
| Action | Inhibit | “CDR132L, a specific antisense oligonucleotide, is a first-in-class miR-132 inhibitor” PMID 33245749 ↗ Jan 2021 |
| Modality | Antisense oligonucleotide | “CDR132L is a synthetic antisense oligonucleotide (ASO)” NCT05350969 ↗ |
| Route | Intravenous | “CDR132L 5 mg/kg body weight intravenous in single dose on Day 1, Day 29 and Day 57” NCT05350969 ↗ |
| Target | MIR132 | “a selective inhibitor of microRNA-132-3p (miR-132)” NCT05350969 ↗ |